🔗 Share this article Patients Coming Off Weight-Loss Jabs Gain Back Weight at a Quadrupled Rate Compared to People Using Diet and Exercise Weight management often requires ongoing approaches. Fresh analysis indicates that individuals who come off new slimming jabs like Wegovy and Mounjaro may regain reduced body mass much more quickly than those who halt conventional diet and exercise regimens. Findings released in a leading health publication shows that while overweight people frequently drop about a fifth of their total mass while on the medication, the mass is regained at an average rate of 0.8 kg per month after stopping. "Users buying these drugs must be cognizant of the risk of quick rebound weight gain when the treatment is stopped," stated researcher Dr. Susan Jebb. This pace of recovery suggests a return to starting mass within about 18 months. Analyzing Therapies The analysis, which looked at 37 of studies involving thousands of patients, compared the results of the injectable medications with other pills. Scientists note that people who lose weight through dieting usually see a slower weight regain—approximately 100 grams monthly—once they finish. The Reason for the Quick Rebound Experts propose the way of the drugs explains the accelerated weight return. GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates appetite. "Artificially providing GLP-1 levels several times higher than the body's typical production might result in the system to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert. "Stopping of this medication means appetite is uncontrolled, making binge eating far more likely." A Chronic Condition? Health authorities recommend the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications. Professionals say that, given the likelihood of weight regain, the treatment is often ongoing. This opinion is echoed by drug manufacturers, who state that the findings "highlight the persistent character of obesity," similar to managing diseases like hypertension. User Experiences Individuals who have come off the jabs report a sudden return of cravings. "It was like something that goes on and I was suddenly ravenous," described one woman. The struggle is compounded if users have not established permanent lifestyle or habit modifications during treatment. Significant Use Survey data suggest that a significant number of people in the UK have used weight-loss jabs in the past year, with demand remaining high. Adoption is greater among women than males. The middle-aged demographic shows the greatest level of interest. Many access the medications through private prescriptions rather than public health services. Ultimately, clinicians emphasize that while these medications are effective tools for shedding pounds, they are not a permanent fix and lasting health benefits likely depends on combined behavioural management.
Weight management often requires ongoing approaches. Fresh analysis indicates that individuals who come off new slimming jabs like Wegovy and Mounjaro may regain reduced body mass much more quickly than those who halt conventional diet and exercise regimens. Findings released in a leading health publication shows that while overweight people frequently drop about a fifth of their total mass while on the medication, the mass is regained at an average rate of 0.8 kg per month after stopping. "Users buying these drugs must be cognizant of the risk of quick rebound weight gain when the treatment is stopped," stated researcher Dr. Susan Jebb. This pace of recovery suggests a return to starting mass within about 18 months. Analyzing Therapies The analysis, which looked at 37 of studies involving thousands of patients, compared the results of the injectable medications with other pills. Scientists note that people who lose weight through dieting usually see a slower weight regain—approximately 100 grams monthly—once they finish. The Reason for the Quick Rebound Experts propose the way of the drugs explains the accelerated weight return. GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates appetite. "Artificially providing GLP-1 levels several times higher than the body's typical production might result in the system to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert. "Stopping of this medication means appetite is uncontrolled, making binge eating far more likely." A Chronic Condition? Health authorities recommend the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications. Professionals say that, given the likelihood of weight regain, the treatment is often ongoing. This opinion is echoed by drug manufacturers, who state that the findings "highlight the persistent character of obesity," similar to managing diseases like hypertension. User Experiences Individuals who have come off the jabs report a sudden return of cravings. "It was like something that goes on and I was suddenly ravenous," described one woman. The struggle is compounded if users have not established permanent lifestyle or habit modifications during treatment. Significant Use Survey data suggest that a significant number of people in the UK have used weight-loss jabs in the past year, with demand remaining high. Adoption is greater among women than males. The middle-aged demographic shows the greatest level of interest. Many access the medications through private prescriptions rather than public health services. Ultimately, clinicians emphasize that while these medications are effective tools for shedding pounds, they are not a permanent fix and lasting health benefits likely depends on combined behavioural management.